Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 561  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
 :: Next article
 :: Previous article 
 :: Table of Contents
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (199 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  Mechanisms of Pr...
 ::  Perspectives
 ::  Acknowledgements
 ::  References

 Article Access Statistics
    Viewed9393    
    Printed167    
    Emailed3    
    PDF Downloaded522    
    Comments [Add]    
    Cited by others 6    

Recommend this journal


 


 
VIEW POINT
Year : 2006  |  Volume : 52  |  Issue : 4  |  Page : 321-324

How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations


1 Laboratory of Pathology, Faculty of Medicine, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium
2 Biomedical Parasitology, Institute Pasteur, Rue du Dr. Roux, Paris, France

Date of Submission04-Aug-2006
Date of Decision14-Oct-2006
Date of Acceptance22-Sep-2006

Correspondence Address:
S Chatterjee
Laboratory of Pathology, Faculty of Medicine, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp
Belgium
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 17102561

Rights and PermissionsRights and Permissions




How to cite this article:
Chatterjee S, Perignon J L, Van Marck E, Druilhe P. How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations. J Postgrad Med 2006;52:321-4

How to cite this URL:
Chatterjee S, Perignon J L, Van Marck E, Druilhe P. How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations. J Postgrad Med [serial online] 2006 [cited 2020 Aug 10];52:321-4. Available from: http://www.jpgmonline.com/text.asp?2006/52/4/321/28168


Immunization against the pre-erythrocytic stages of malaria has attracted considerable efforts, since it induces a strong, sterile protection in humans upon vaccination with live radiation-attenuated, sporozoite stage parasites. Irradiated sporozoites readily transform but become blocked at the liver stage of development in vivo. The same method also induces protection in various mouse models currently used in laboratory research.[1],[2],[3] This parallelism between mice and humans would at a first glance provide support to the relevance of the rodent model.

There are however major differences between the two situations that deserve to be stressed: A single immunization with 1000 P. berghei ANKA (Antwerpen-Kasapa) strain-irradiated sporozoites can induce protection in some strains of laboratory models such as BALB/c or A/J inbred mice. In other strains of mice such as C57BL/6, three immunisations with 30,000 irradiated sporozoites are required to induce protection.[4]

In humans by contrast, the number of doses required to elicit protection is much higher: protection to P. falciparum was inconsistently achieved after 12-14 exposures to hundreds of irradiated mosquitoes in vaccination protocols lasting over a year, whereas 8-10 immunizations proved ineffective.[5],[6],[7]

In terms of susceptibility to infection, there are also large differences from one host to the other: Humans are extremely susceptible, 1-2 mosquito bites delivering a dozen sporozoites are followed by a blood infection. C57BL/6 mice are highly susceptible to the development of P. berghei (but difficult to protect from malaria), whereas the BALB/c mice are poorly susceptible to P. berghei infection (but readily protected).[4] Therefore, protection appears to be inversely correlated to the susceptibility of the host to sporozoite infection, the natural host being both highly susceptible to infection and difficult to protect.

Consideration of this led us to launch studies of P. berghei in Grammomys surdaster, a natural host-parasite combination in which natural infection evolves in a chronic manner (in contrast to laboratory rodents in which high parasite loads and death are the most frequent outcome). Surveys of wild rodents revealed chronic Plasmodium carriage at low density.[8] The same is observed with human parasites in repeatedly exposed individuals.[9] G. surdaster are exquisitely susceptible to infection since < 12 sporozoites could induce a blood infection, but they are extremely difficult to protect. Immunization schedules effective in laboratory rodents such as BALB/c mice and C57BL/6 mice failed to protect G. surdaster .[10] Five immunizations with 30,000 irradiated sporozoites provided protection in only a fraction of immunized animals and did not prevent death (Van Ham and Coosemans, personal communication). A higher dose of 100,000 irradiated sporozoites was also ineffective. Similar results were obtained when using Thamnomys gazellae, the natural host of P. yoelii (S. Chatterjee, unpublished). The similarity of behaviour of P. berghei in G. surdaster and of P. falciparum in humans appears as a valuable advantage, as compared to models currently used.

One drawback however to the present use of the Grammomys is that they are difficult to breed, are not commercially available and their immune system is poorly characterized. In the absence of any other alternative natural rodent host system, the Grammomys model needs to be better characterised, especially for immune responses. At present a small colony of Grammomys surdaster is mantained in the Netherlands and could be offered to researchers developing malaria vaccines, to test their efficacy. Thus rather than focussing on a single mouse strain or a single host species to test vaccine efficacy, researchers could select such natural host-parasite systems of Grammomys - P. berghei or man - P. falciparum . In the latter case, malaria challenges and vaccinations may need to be attempted on a background of previous or current infection with malaria or other parasites and pre-existing immunity to malaria; which is the case for many humans in need of vaccination.


 :: Mechanisms of Protection in Natural Versus Artificial Models Top


The distinct pattern of susceptibility to infection/ease of induction of protection suggests distinct protective mechanisms and reduces confidence that initial vaccine successes in animal models can be scaled up in humans. This is well illustrated by the recent history of pre-erythrocytic malaria vaccines. These were initially aimed at inducing only sporozoite neutralizing antibodies (based on mAb passive transfer experiments in mice), then at inducing CD8-CTLs destroying infected hepatocytes Later reports however have identified CD4-IFN-gamma secreting cells as a critical component of defence.[11]

Each of these quite different approaches are derived from results gathered in models. They have absorbed decades of research and considerable amounts of money, yet cannot predict with surety the efficacy of similar vaccines in humans. The most successful Plasmodium vaccine used to date, RTS/S, relies on an adjuvant inducing optimal CTL activity in models. In humans it induces very high antibody levels,[12] no CTL activity, yet generates a degree of protection. These recent experiences clearly show that mechanisms of protection in artificial models differ from those in natural hosts and draw attention to four aspects: (a) innate immunity, (b) targets of adaptive immunity, (c) molecular mimicry and (d) efficacy of defence mechanisms depending on the host.

a. The innate immune response prevalent in unnatural hosts (rats, mice) is characterized by an infiltrate of mononuclear cells, neutrophils and eosinophils around late stage schizonts and emerging merozoites.[13],[14],[15],[16],[17] In contrast it is absent in the natural host, Grammomys.[10] The lower susceptibility of artificial hosts could be explained by the stronger local intra-hepatic innate response.

b. Recent experiments established that liver forms resulting from irradiated sporozoites are both persistent and essential for protection.[18],[19],[20],[21],[22],[23] However, in laboratory mice, both immunizing and challenge sporozoites were arrested at the uninucleate, trophozoite stage.[18],[19] This is in contrast to observations of P. berghei in Grammomys and P. falciparum in chimpanzees (Thomas A. and Druilhe, unpublished), where development to submature schizonts were noted.[10] This suggests distinct targets, as well as distinct immune mechanisms.

c. The host specificity of a given parasite relies in great part on molecular mimicry i.e., on the antigen "compatibility" between a given parasite and its usual hosts.[20] Understandably, when the same parasite is introduced in an abnormal host, even one that is phylogenetically closely related, the number of shared epitopes will be less. This dramatically increases the number of targets for effector mechanisms and may explain, at least in part, the greater effectiveness of vaccines against a given parasite in an abnormal host.

d. Finally, the efficacy of defence mechanisms depends on the host, a fact often overlooked. A telling example comes from sporozoite-hepatocyte interactions. When examining the effect of inhibitory antibodies, diametrically opposite results were obtained when using the same antibodies with either human hepatocytes or the human Hep-G2 hepatoma that is the closest known to normal hepatocytes.[11]

To summarize, the "adaptation" of a parasite to an artificial host actually translates in immunological terms into defence mechanism that in most circumstances are more effective than those seen in the natural host. Since we do not understand well-enough human immunity to Plasmodia, it is not possible to determine which model if any may best reflect the desired pattern of immune responses. Similar situations prevail for other parasites, e.g., Schistosomes.[24],[25],[26],[27],[28],[29],[30],[31],[32],[33],[34],[35],[36],[37],[38],[39] Models can be at best considered marginally valuable until results have been ascertained using the same parasite in its natural host.


 :: Perspectives Top


In today's post-genomic era with Plasmodia, Anopheles and human genomes at hand, optimism abounds that new therapies and vaccines will emerge.[40],[41],[42],[43],[44],[45] However, researchers have become even more dependent upon models for screening molecules involved in protection. The existing models seem to be employed based more on availability in laboratory settings than on demonstrated relevance. Consequently vaccine candidates that show promise in a given model might fail in humans or worse, experimental results may lead to the rejection of vaccine candidates that would be effective in humans. Each transfer between species - from rodents to non-human primates to humans - involves assumptions that are rarely questioned. Since animal models will play an even more crucial position there is an urgent need for an improved evaluation of their merits and limitations.

The dilemma can be summarized as follows: either we rely on substantially more difficult models for vaccine development (e.g. humans, Grammomys) and accept that progress will be slow, though results should be more relevant; or, we continue to employ easier models, generating data which may not be extrapolated to the target host!

In fact, there might be a third way - though unlikely to be implemented. Indeed, it would require a strong commitment to gather an improved understanding of essential defence mechanisms prevailing in humans, this leading to improved models that reflect them best. In the field of malaria pre-erythrocytic vaccine development, the strategy would require (a) the induction of protection by irradiated sporozoites in a sufficient number of volunteers and (b) better definition of naturally occurring pre-erythrocytic stage immunity under field conditions, together with an analysis of the immune responses associated with protection in those two situations.[46] Based on this knowledge, the rational choice of an improved model, as well as the development of novel ones, could be envisaged.

Modern genomics may provide valuable alternatives for the selection of both the parasite and the host. For instance, availability of the full genomes of most rodent plasmodia may lead to the selection of a preferred rodent plasmodium species based on knowledge of molecular homologies with the corresponding human plasmodium gene. The same can apply to the selection of the best fit between host molecules. Another approach promoted by some groups is gene replacement to substitute P. falciparum genes for rodent plasmodium genes and similarly, to substitute human genes for mouse ones. Finally, the successful grafting of human hepatocytes into immunodeficient mice opens novel areas of research where the interaction of human plasmodium sporozoites with their normal host cells can be dissected in an experimental model.[47]

The delays and investments needed to develop improved models have to be balanced by the ethical and financial concerns, associated with the rising number of clinical trials performed in human volunteers with vaccine formulations designed in insufficiently documented models.


 :: Acknowledgements Top


We would like to acknowledge the initiation, support and encouragement of Professor Marc Wιry in the Grammomys work mentioned in this paper. This work was supported by the Inter-University Poles of Attraction Program (Grant P5/20) Services of the Prime Minister Federal Agency for Scientific, Technical and Cultural Affairs and by the European Commission programmes STD 2, 3 and INCO DC (grants TS 2-M-0122-F, ERB 350 4PL 910123, EC*18 CT 950016).

 
 :: References Top

1.Nussenzweig RS, Vanderberg J, Spitalny GL, Rivera CI, Orton C, Most H. Sporozoite induced immunity in mammalian malaria. A review. Am J Trop Med Hyg 1972;21:722-8.   Back to cited text no. 1    
2.Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, et al . Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002;185:1155-64.  Back to cited text no. 2    
3.Orjih AU, Cochrane AH, Nussenzweig RS. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei . Trans R Soc Trop Med Hyg 1982;76:57-61.  Back to cited text no. 3  [PUBMED]  
4.Jaffe RI, Lowell GH, Gordon DM. Differences in susceptibility among mouse strains to infection with Plasmodium berghei (ANKA clone) sporozoites and its relationship to protection by gamma-irradiated sporozoites. Am J Trop Med Hyg 1990;42:309-13.  Back to cited text no. 4  [PUBMED]  
5.Herrington D, Davis J, Nardin E, Beier M, Cortese J, Eddy H, et al . Successful immunization of humans with irradiated malaria sporozoites: Humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991;45:539-47.  Back to cited text no. 5    
6.Edelman R, Hoffman SL, Davis JR, Beier M, Sztein MB, Losonsky G, et al . Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 1993;168:1066-70.  Back to cited text no. 6    
7.Bray RS. Vaccination against Plasmodium falciparum : A negative result. Trans R Soc Trop Med Hyg 1976;70:258.  Back to cited text no. 7  [PUBMED]  
8.Vincke IH, Lips M. Un nouveau plasmodium d'un rongeur sauvage du Congo, Plasmodium berghei N.Sp. Ann Soc Belge Mιd Trop 1948;25:97-102.   Back to cited text no. 8    
9.Yazdani SS, Mukherjee P, Chauhan VS, Chitnis CE. Immune responses to asexual blood-stages of malaria parasites. Curr Mol Med 2006;6:187-203.  Back to cited text no. 9  [PUBMED]  
10.Chatterjee S, Ngonseu E, Van Overmeir C, Correwyn A, Druilhe P, Wιry M. Rodent malaria in the natural host - irradiated sporozoites of Plasmodium berghei induce liver-stage specific immune responses in the natural host Grammomys surdaster and protect immunized Grammomys against P. berghei sporozoite challenge. Afr J Med Med Sci 2001;30:25-33.  Back to cited text no. 10    
11.Druilhe P. Immunity to liver stages. In: Malaria. Parasite biology. Pathogenesis and Protection (Sherman IW, editor) pp. 513-543. American Society of Microbiology: 1998.  Back to cited text no. 11    
12.Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, Doherty T, et al . Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 2003;68:97-101.  Back to cited text no. 12    
13.Khan ZM, Vanderberg JP. Role of host cellular response in differential susceptibility of nonimmunized BALB/c mice to Plasmodium berghei and P. yoelii sporozoites. Infect Immun 1991;59:2529-34.  Back to cited text no. 13    
14.Khan ZM, Vanderberg JP. Eosinophil-rich, granulomatous inflammatory response to Plasmodium berghei hepatic schizonts in non-immunized mice is age-related. Am J Trop Med Hyg 1991;45:190-201.  Back to cited text no. 14  [PUBMED]  
15.Vanderberg JP, Khan ZM, Stewart MJ. Induction of hepatic inflammatory response by Plasmodium berghei sporozoites protects BALB/c mice against challenge with Plasmodium yoelii sporozoites. J Parasitol 1993;79:763-7.  Back to cited text no. 15  [PUBMED]  
16.Meis JF, Jap PH, Hollingdale MR, Verhave JP. Cellular response against exoerythrocytic forms of Plasmodium berghei in rats. Am J Trop Med Hyg 1987;37:506-10.  Back to cited text no. 16  [PUBMED]  
17.Bafort JM. The biology of rodent malaria with particular reference to Plasmodium vinckei vinckei rodhain. Ann Soc Belge Mιd Trop 1971;51:5-203.   Back to cited text no. 17    
18.Scheller LF, Wirtz RA, Azad AF. Susceptibility of different strains of mice to hepatic infections with Plasmodium berghei . Infect Immun 1994;62:4844-7.  Back to cited text no. 18  [PUBMED]  [FULLTEXT]
19.Londono JA, Sedegah M, Charoenvit Y, Beaudoin RL, Druilhe P. Antigenic analysis of Plasmodium yoelii liver stages by fluorescence antibody assays. Trop Med Parasitol 1991;42:381-5.  Back to cited text no. 19  [PUBMED]  
20.Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic stages derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995;92:4066-8.  Back to cited text no. 20  [PUBMED]  [FULLTEXT]
21.Scheller LF, Stump KC, Azad AF. Plasmodium berghei : Production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice. J Parasitol 1995;81:58-62.  Back to cited text no. 21  [PUBMED]  
22.Khan ZM, Ng C, Vanderberg JP. Early hepatic stages of Plasmodium berghei : Release of circumsporozoite protein and host cellular inflammatory response. Inf Imm 1992;60:264-70.  Back to cited text no. 22  [PUBMED]  [FULLTEXT]
23.Hoffman SL. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 1989;244:1078-81.  Back to cited text no. 23    
24.Rollinson D, Southgate VR. The genus Schistosoma: A taxonomic appraisal. In The Biology of Schistosomes (Rollinson D, Simpson AJ, editors). Academic Press: 1987. p. 1-49.  Back to cited text no. 24    
25.Minard P, Dean DA, Jacobson RH, Vannier WE, Murrell KD. Immunization of mice with cobalt-60 irradiated Schistosoma mansoni cercariae. Am J Trop Med Hyg 1978;27:76-86.  Back to cited text no. 25    
26.Majid AA, Marshall TF, Hussein MF, Busharo HO, Taylor MG, Nelson GS, et al . Observations on cattle schistosomiasis in the Sudan, a study in comparative medicine. III Field testings of an irradiated schistosoma bovis vaccine. Am J Trop Med Hyg 1980;29:452-5.  Back to cited text no. 26    
27.Wynn TA, Oswald IP, Eltoum IA, Caspar P, Lowenstein CJ, Lewis FA, et al . Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni. J Immunol 1994;153:5200-9.  Back to cited text no. 27    
28.Eberl M, Langermans JA, Frost PA, Vervenne RA, van Dam GJ, Deelder AM, et al . Cellular and humoral immune responses and protection against schistosomes induced by a radiation - Attenuated vaccine in chimpanzees. Inf Imm 2001;69:5352-62.  Back to cited text no. 28    
29.Capron A, Capron M, Dombrowicz D, Riveau G. Vaccine strategies against schistosomiasis: From concepts to clinical trials. Int Arch Allergy Immunol 2001;124:9-15.  Back to cited text no. 29    
30.Ross AG, Sleigh AC, Li Y, Davis GM, Williams GM, Jiang Z, et al . Schistosomiasis in the People's Republic of China: Prospects and challenges for the 21rst century. Clin Microbiol Rev 2001;14:270-95.  Back to cited text no. 30    
31.Dean DA. Schistosoma and related genera: Acquired resistance in mice. Exp Parasitol 1983;55:1-104.  Back to cited text no. 31    
32.Warren KS. The contribution of worm burden and host response to the development of hepato-splenic schistosomiasis mansoni in mice. Am J Trop Med Hyg 1963;12:34-9.  Back to cited text no. 32    
33.Smythies LE, Pemberton RM, Coulson PS, Mountford AP, Wilson RA. T-cell-derived cytokines associated with pulmonary immune mechanisms in mice vaccinated with irradiated cercariae of Schistosoma mansoni. J Immunol 1992;148:1512-8.  Back to cited text no. 33    
34.Betts CJ, Wilson RA. Th1 cytokine mRNA expression dominates in the skin-draining lymph nodes of C57BL6 mice following vaccination with irradiated Schistosoma mansoni cercariae, but is down-regulated upon challenge infection. Immunol 1998;93:49-54.  Back to cited text no. 34    
35.Pearce EJ, Sher A. Functional dichotomy in the CD4+ T cell response to Schistosoma mansoni. Exp Parasitol 1991;73:110-6.  Back to cited text no. 35    
36.Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991;349:243-5.  Back to cited text no. 36    
37.Rihet P, Demeure CE, Bourgois A, Prata A, Dessein AJ. Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur J Immunol 1991;21:2679-86.  Back to cited text no. 37    
38.Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, et al . Immunity after treatment of human schistosomiasis: Association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992;22:1483-94.  Back to cited text no. 38    
39.Marquet S, Abel L, Hillaire D, Dessein H, Kalil J, Feingold J, et al . Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet 1996;14:181-4.   Back to cited text no. 39    
40.Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al . Genome sequence of the human malaria parasite Plasmodium falciparum . Nature 2002;419:498-511.  Back to cited text no. 40    
41.Holt RA, Subramanian GM, Halpern A, Sutton GG, Charlab R, Nusskern DR, et al . The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002;298:129-49.  Back to cited text no. 41    
42.Carlton JM, Angiuoli SV, Suh BB, Kooij TW, Pertea M, Silva JC, et al . Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii. Nature 2002;419:512-9.  Back to cited text no. 42    
43.Florens L, Washburn MP, Raine JD, Anthony RM, Grainger M, Haynes JD, et al . A proteomic view of the Plasmodium falciparum life cycle. Nature 2002;419:520-6.  Back to cited text no. 43    
44.Maher BA. The hopes and realities of the Plasmodium falciparum genome. The Scientist 2002;16:24-7.  Back to cited text no. 44    
45.Chauhan VS, Bhardwaj D. Current status of malaria vaccine development. Adv Biochem Eng Biotechnol 2003;84:143-82.  Back to cited text no. 45    
46.Daubersiers P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, et al . Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000;6:1258-63.  Back to cited text no. 46    
47.Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, et al . Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;8:927-33.  Back to cited text no. 47    



This article has been cited by
1 Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity
Perlaza, B.-L., Sauzet, J.-P., Brahimi, K., Benmohamed, L., Druilhe, P.
Malaria Journal. 2011; 10(art 27)
[Pubmed]
2 Development of anti-malarial vaccines and need for clinical trials in accordance with international standards in South Africa | [Le développement de vaccins antipaludiques et la nécessité des essais cliniques conformes aux normes internationales en Afrique]
Doumbo, O.K., Djimdé, A.A., Théra, M.A.
Bulletin de la Societe de Pathologie Exotique. 2008; 101(3): 249-253
[Pubmed]
3 Blood-stage challenge for malaria vaccine efficacy trials: A pilot study with discussion of safety and potential value
Sanderson F, Andrews L, Douglas AD, et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE. 2008; 78(6): 878-883
[Pubmed]
4 Novel vaccines and adjuvant systems - The utility of animal models for predicting immunogenicity in humans
Davis HL
HUMAN VACCINES. 2008; 4(3): 246-250
[Pubmed]
5 Pre-erythrocytic stage malaria vaccines: time for a change in path
Druilhe P, Barnwell JW
CURRENT OPINION IN MICROBIOLOGY. 2007; 10 (4): 371-378
[Pubmed]
6 Progress and challenges towards the development of malaria vaccines
Tetteh KKA, Polley SD
BIODRUGS. 2007; 21 (6): 357-373
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow